- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Welcome from AACR Chief Executive Officer
Margaret Foti
American Association for Cancer Research, Philadelphia, PA, United States
- Free
- slides video
- audio + slides
- All slides included
Welcome from Scientific Committee Chair
Ari M Melnick
Weill Cornell Medical College, New York, NY, United States
- Free
- audio + slides
- Some slides withheld
Keynote Address: Immunogenicity Predicts Prevention
Michael A Caligiuri
City of Hope National Medical Center, Duarte, CA, United States
- Free
- audio + slides
- Some slides withheld
Keynote Address: CAR T for lymphoma and beyond
Carl H June
Univ. of Pennsylvania, Philadelphia, PA, United States
- Free
- audio + slides
- All slides included
Panel Discussion
Ari M Melnick
Weill Cornell Medical College, New York, NY, United States
Michael A Caligiuri
City of Hope National Medical Center, Duarte, CA, United States
Carl H June
Univ. of Pennsylvania, Philadelphia, PA, United States
- Free
- slides video
- audio + slides
- All slides included
Panelist
Cheryl A London
Tufts Medical Center, Boston, MA, United States
Laura Marconato
Centro Oncologico Veterinario, Sasso Marconi, Italy
- Free
- slides video
- audio + slides
- All slides included
Panelist
Lisa G. Roth
Weill Cornell Medical College of Cornell University, New York, NY, United States
Kieron Dunleavy
George Washington Univ., Washington, DC, United States
- Free
- audio + slides
- Some slides withheld
Precision medicine based on the genetic taxonomy of DLBCL
Louis M Staudt
National Cancer Institute, Bethesda, MD, United States
- Free
- slides video
- audio + slides
- All slides included
How to design a MATCH trial for lymphoma
Anas Younes
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Practical considerations for using genome sequencing data for patient selection
David W. Scott
BC Cancer, Vancouver, BC, Canada
- Free
- audio + slides
- Some slides withheld
Molecular typing in DLBL: Subset and match?
Peter W M Johnson
Univ. of Southampton, Southampton, United Kingdom
- Permission not
granted for presentation
Utilizing genomic sequencing from clinical assays in lymphoma management
Connie Batlevi
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
- Free
- Coming soon
- All slides included
Panel Discussion
Connie Batlevi
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
Louis M Staudt
National Cancer Institute, Bethesda, MD, United States
Anas Younes
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
Peter W M Johnson
Univ. of Southampton, Southampton, United Kingdom
David W. Scott
BC Cancer Agency, Vancouver, BC, Canada
- Free
- slides video
- audio + slides
- All slides included
Drugs in the curative RCHOP combination exhibit low cross-resistance but not pharmacologic synergy
Adam C Palmer
Harvard Medical School, Boston, MA, United States
- Permission not
granted for presentation
MHC class II expression is associated with a distinct mutational profile and immune cell landscape of the microenvironment in GCB-DLBCL
Daisuke Ennishi
BC Cancer Agency, Vancouver, BC, Canada
- Free
- audio + slides
- Some slides withheld
DNA and histone methylation as therapeutic targets in lymphoma
Ari M Melnick
Weill Cornell Medical College, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Targeting EZH2 in lymphoma
Vincent Ribrag
Institut Gustave-Roussy, Villejuif, France
- Permission not
granted for presentation
Germinal center-derived lymphomas: At the intersection of genetics and epigenetics
Laura Pasqualucci
Columbia University Institute for Cancer Genetics, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
BET inhibitors in lymphoma
Francesco Bertoni
Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland
- Free
- audio + slides
- Some slides withheld
Circulating tumor DNA to monitor treatment response and detect resistant clones in indolent lymphoproliferative diseases treated with novel therapies
Constantine S. Tam
Peter MacCallum Cancer Center, East Melbourne, Australia
- Free
- slides video
- audio + slides
- All slides included
Tumor fingerprints in the liquid biopsy: Immunoglobulin gene rearrangement or CAPP-seq?
Wyndham E Wilson
National Cancer Institute, Bethesda, MD, United States
- Free
- slides video
- audio + slides
- All slides included
Use of circulating tumor DNA to genotype aggressive lymphomas
Davide Rossi
Università degli Studi del Piemonte Orientale, Vercelli, Switzerland
- Free
- audio + slides
- All slides included
Panel Discussion
Lee M Greenberger
The Leukemia & Lymphoma Society, Rye Brook, NY, United States
Davide Rossi
Università degli Studi del Piemonte Orientale, Vercelli, Switzerland
Constantine S. Tam
Peter MacCallum Cancer Center, East Melbourne, Australia
Wyndham E Wilson
National Cancer Institute, Bethesda, MD, United States
- Free
- slides video
- audio + slides
- All slides included
Using in vivo CRISPR-based screening to identify lymphoma drug targets
Michael T Hemann
David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, United States
- Permission not
granted for presentation
What is the current role and impact of CRISPR screening to define therapeutic targets in lymphoma?
Sandeep S Dave
Duke Univ., Chapel Hill, NC, United States